Exelixis, Inc. (NASDAQ:EXEL) Given Average Rating of “Moderate Buy” by Analysts

Shares of Exelixis, Inc. (NASDAQ:EXEL) have been assigned a consensus recommendation of “Moderate Buy” from the twenty-seven brokerages that are currently covering the firm, MarketBeat Ratings reports. Eleven analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $45.45.

EXEL has been the topic of a number of analyst reports. Oppenheimer reiterated a “market perform” rating and set a $36.00 target price on shares of Exelixis in a report on Wednesday. Zacks Research downgraded Exelixis from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 26th. The Goldman Sachs Group started coverage on Exelixis in a research note on Wednesday, September 17th. They set a “buy” rating and a $47.00 price objective on the stock. Guggenheim downgraded shares of Exelixis from a “buy” rating to a “neutral” rating in a research note on Monday, November 3rd. Finally, Stifel Nicolaus set a $43.00 price objective on shares of Exelixis in a research note on Wednesday.

Exelixis Trading Up 0.0%

Shares of NASDAQ EXEL opened at $40.81 on Friday. The company’s 50-day moving average price is $38.97 and its 200 day moving average price is $40.35. Exelixis has a 52 week low of $31.90 and a 52 week high of $49.62. The stock has a market cap of $10.99 billion, a price-to-earnings ratio of 19.62, a PEG ratio of 0.79 and a beta of 0.32.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.68 by $0.10. The company had revenue of $597.76 million for the quarter, compared to the consensus estimate of $590.04 million. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. The company’s revenue for the quarter was up 10.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.47 earnings per share. Exelixis has set its FY 2025 guidance at EPS. As a group, research analysts expect that Exelixis will post 2.04 earnings per share for the current year.

Hedge Funds Weigh In On Exelixis

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Richardson Financial Services Inc. boosted its holdings in shares of Exelixis by 95.1% in the 3rd quarter. Richardson Financial Services Inc. now owns 599 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 292 shares during the period. Hemington Wealth Management lifted its holdings in Exelixis by 211.3% in the first quarter. Hemington Wealth Management now owns 769 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 522 shares during the last quarter. Root Financial Partners LLC acquired a new position in Exelixis in the third quarter valued at approximately $28,000. Byrne Asset Management LLC boosted its stake in Exelixis by 129.0% in the second quarter. Byrne Asset Management LLC now owns 710 shares of the biotechnology company’s stock valued at $31,000 after acquiring an additional 400 shares during the period. Finally, Luminist Capital LLC grew its holdings in shares of Exelixis by 2,740.0% during the second quarter. Luminist Capital LLC now owns 710 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 685 shares during the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.